Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016;14(5):504-13.
doi: 10.2174/1570159x13666150716165323.

Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications

Affiliations
Review

Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications

Enza Palazzo et al. Curr Neuropharmacol. 2016.

Abstract

Metabotropic glutamate receptor 7 (mGluR7) is localized presynaptically at the active zone of neurotransmitter release. Unlike mGluR4 and mGluR8, which share mGluR7's presynaptic location, mGluR7 shows low affinity for glutamate and is activated only by high glutamate concentrations. Its wide distribution in the central nervous system (CNS) and evolutionary conservation across species suggest that mGluR7 plays a primary role in controlling excitatory synapse function. High mGluR7 expression has been observed in several brain regions that are critical for CNS functioning and are involved in neurological and psychiatric disorder development. Until the recent discovery of selective ligands for mGluR7, techniques to elucidate its role in neural function were limited to the use of knockout mice and gene silencing. Studies using these two techniques have revealed that mGluR7 modulates emotionality, stress and fear responses. N,N`-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082) was reported as the first selective mGluR7 allosteric agonist. Pharmacological effects of AMN082 have not completely confirmed the mGluR7-knockout mouse phenotype; this has been attributed to rapid receptor internalization after drug treatment and to the drug's apparent lack of in vivo selectivity. Therefore, the more recently developed mGluR7 negative allosteric modulators (NAMs) are crucial for understanding mGluR7 function and for exploiting its potential as a target for therapeutic interventions. This review presents the main findings regarding mGluR7's effect on modulation of synaptic function and its role in normal CNS function and in models of neurologic and psychiatric disorders.

PubMed Disclaimer

Conflict of interest statement

All the authors have read and approved the paper and have not any financial or other relationships that might lead to a conflict of interest.

Figures

Fig. (1)
Fig. (1)
Synaptic distribution of mGluRs with group I localized mainly postsynaptically and group II and III localized presynaptically. The mGluR7 receptor is found on both glutamatergic and GABAergic terminals, functioning as an auto- and hetero-receptor and controlling neurotransmitter release. Together with excitatory amino acid transporters (EAAT), presynaptic mGluR7 receptors reduce glutamate levels under conditions of high glutamate concentration. mGluR7 binding and signaling proteins are also reported. VGAT, vesicular GABA transporter; vGluT, vesicular glutamate transporter; EAAT, excitatory amino acid transporter; NMDA, N-methyl-D-aspartate receptor; AMPA, a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, KA, kainic acid receptor, CaM, Ca2+-calmodulin complex, PKC, protein kinase C, AC, adenylate cyclase, PICK1, PDZ domain-containing protein, Ca2+, N type Ca2+ channels, GIRKs, G-protein-coupled inwardly rectifying potassium channels.

Similar articles

Cited by

References

    1. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997;37:205–237. [http://dx.doi.org/10.1146/annurev.pharmtox.37.1.205]. [PMID: 9131252]. - PubMed
    1. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 2005;4(2):131–144. [http://dx.doi.org/10.1038/nrd1630]. [PMID: 15665858]. - PubMed
    1. Ferraguti F., Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res. 2006;326(2):483–504. [http://dx.doi.org/10.1007/ s00441-006-0266-5]. [PMID: 16847639]. - PubMed
    1. Ritter S.L., Hall R.A. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 2009;10(12):819–830. [http://dx.doi.org/10.1038/nrm2803]. [PMID: 19935667]. - PMC - PubMed
    1. Shigemoto R., Kulik A., Roberts J.D., Ohishi H., Nusser Z., Kaneko T., Somogyi P. Target-cell-specific concentration of a metabotropic glutamate receptor in the presynaptic active zone. Nature. 1996;381(6582):523–525. [http://dx.doi.org/10.1038/ 381523a0]. [PMID: 8632825]. - PubMed

MeSH terms

Substances